Table. 1 Clinical trials of mesenchymal stem cells and tumors.
From: Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Clinical trial purposes | ClinicalTrials.gov Identifier | Conditions | Interventions | Phase | Status |
|---|---|---|---|---|---|
Treatment of tumors | NCT03896568 | Recurrent high-grade Glioma | BM-hMSCs-DNX2401 | Phase I | Recruiting |
NCT05699811 | Locally advanced or metastatic solid tumors | MSC-IFNα | Phase I/II | Recruiting | |
NCT01129739 | MDS | UC-MSCs/Placenta-derived MSCs | Phase II | Unknown status | |
NCT04758533 | DIPG/Medulloblastoma | AloCELYVIR (MSCs + ICOVIR-5) | Phase I/II | Recruiting | |
NCT05113342 | Relapsed/Refractory multiple Myeloma | Allogeneic MSCs (Descartes-25) | Phase I/II | Recruiting | |
NCT05047276 | Metastatic uveal melanoma | AloCelyvir (MSCs + OVs) | Phase I/II | Not yet recruiting | |
NCT05789394 | Recurrent GBM | Allogeneic adipose-derived MSCs | Phase I | Recruiting | |
NCT02068794 | Gynecologic tumors | Adipose tissue derived MSCs | Phase I/II | Recruiting | |
NCT02079324 | Head and neck cancer | Genetically modified MSCs | Phase I | Unknown status | |
NCT01844661 | Solid tumors | CELYVIR (bone marrow-derived autologous MSCs infected with ICOVIR5) | Phase I/II | Completed | |
NCT04087889 | Pancreatic cancer | Allogeneic Adipose-derived MSCs | Not described | Unknown status | |
NCT04657315 | GBM | MSC11FCD | Phase I/II | Completed | |
NCT03298763 | NSCLC | MSCTRAIL (TRAIL + MSCs) | Phase I/II | Recruiting | |
NCT00851162 | Bone neoplasms | MSCs | Phase II/III | Withdrawn | |
NCT03184935 | MDS | Human UC-MSCs | Phase I/II | Suspended | |
NCT02530047 | Ovarian cancer | MSC-INFβ | Phase I | Completed | |
NCT02804945 | Malignancies | MSCs | Phase I | Completed | |
NCT01983709 | Prostate cancer | Allogeneic human MSCs | Phase I | Terminated | |
About hematopoietic stem cell transplantation | NCT01092026 | Allogeneic stem cell transplantation | MSCs | Phase I/II | Unknown status |
NCT01624701 | Chronic leukemia/MDS/ Lymphoma/Myeloma | MSCs | Phase I/II | Terminated | |
NCT02032446 | Hematologic malignancies | UC-MSCs | Phase I/II | Unknown status | |
NCT00361049 | cancer | MSCs infusion | Phase I | Completed | |
NCT02181478 | ALL/AML/NHL/HL/CLL/CML/MDS/MF | MSCs transplantation | Phase I | Completed | |
NCT00081055 | Hematologic malignancies | Autologous expanded MSCs OTI-010 | Phase II | Withdrawn | |
NCT00498316 | MDS/Leukemia | Cord blood expansion on MSCs | Phase I | Completed | |
NCT01045382 | Hematologic malignancies | MSCs | Phase II | Terminated | |
NCT00504803. | Hematologic malignancies | MSCs infusion | Phase II | Completed | |
NCT03106662 | Hematopoietic stem cell transplantation | MSCs | Phase III | Completed | |
NCT00447460 | Patients with hematologic malignancies have GVHD after transplantation | MSCs | Phase I/II | Completed | |
Reduce the side effects caused by anti-tumor | NCT02648386 | Erectile dysfunction after rectal cancer treatment. | NeuroRegen scaffold/UC-MSCs transplantation | Phase I/II | Unknown status |
NCT02509156 | Cardiomyopathy due to anthracyclines | Allo-MSCs | Phase I | Completed | |
NCT01275612 | Cisplatin-induced acute renal failure | MSCs infusion | Phase I | Withdrawn | |
NCT02962661 | Anthracycline-associated cardiomyopathy | Intravenous infusion or transendocardial injection of MSCs | Phase I | Recruiting | |
NCT05672420 | Treatment-induced myelosuppression in patients with hematologic malignancies | UC-MSCs | Phase I/II | Not yet recruiting | |
NCT04007081 | Radiation xerostomia | Autotransplantation of marrow MSCs | Not Applicable | Completed | |
NCT04489732 : | Xerostomia following radiotherapy | MSCs | Phase I | Active, not recruiting | |
NCT03874572 | Radiation-induced hyposalivation and xerostomia | Allogeneic MSCs | Phase I | Active, not recruiting | |
NCT05820711 | Patients with xerostomia after radiotherapy for head and neck cancer | MSCs | Phase I | Recruiting | |
NCT04776538 | Xerostomia following radiotherapy | MSCs | Phase II | Recruiting | |
NCT03876197 | Xerostomia due to radiotherapy | Autologous adipose-derived MSCs | Phase I/II | Enrolling by invitation |
